Deargen Inc. signed a strategic technology partnership agreement with Uppthera Inc.
Read More
Prediction of origin of cancer by deep-learning analysis using pan-cancer transcriptome
We introduce DEARGEN’s research results on the model that predicts the primary cancer sites through the gene expression profile.
Read More
CWx (Cascaded Wx): Technology for Prognosis Biomarker Discovery
Deargen has announced the research results on an AI technology CWx that can discover biomarkers on disease prognosis.
Read More
WX: Technology for Novel Biomarker Discovery
Deargen has announced research results on an AI technology Wx that can discover novel biomarkers.
Read More
Deargen, Selected for the TIPS Program with Genomic Data Analysis Service
Deargen was selected for the TIPS program, so it will receive a total of $600,000 in R & D expenses from the operator Medytox Venture Investment.
Read More
Genomic Data Analysis Platform ‘DearTRANS’ Beta Service Launch
Deargen launches a beta service of ‘DearTRANS’ that is a cloud-based genomic big data analysis platform.
Read More
The Challenge to Conquer Cancer, Prognostic Prediction Analysis of Lung Cancer Using AI
Deargen has been selected for the 2017 National Program for Cancer Control.
Read More
Deargen was selected as Top Performers of the NCI-CPTAC DREAM Challenge
Deargen was selected as a Top Performer of the NCI-CPTAC DREAM Proteogenomics Computational Challenges.
Read More
Deargen, Won at ILSVRC 2016 (ImageNet Large Scale Visual Recognition Challenge)
Deargen was voted in the top 10 in the world at the ‘ImageNet Large Scale Visual Recognition Challenge (ILSVRC) 2016’.
Read More